Clinical Trials
15 trialsNCT05978141 2026-05-20
A Registry for People With T-cell Lymphoma
Memorial Sloan Kettering Cancer Center
Recruiting
NCT07525466 2026-04-13
Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
Beijing Tongren Hospital
Phase 1/2 Recruiting
NCT07382817 2026-02-27
Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06069830 2026-01-27
ENKTL
Ruijin Hospital
Phase NA Recruiting
NCT07162012 2025-12-02
Anti-EBV TCR-T
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1 Recruiting
NCT01137643 2025-10-27
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
Recruiting
NCT04288726 2025-07-20
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Baylor College of Medicine
Phase 1 Recruiting
NCT00935090 2025-07-08
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
Recruiting
NCT01137825 2025-06-25
Registry of Older Patients With Cancer
UNC Lineberger Comprehensive Cancer Center
Recruiting
NCT07000617 2025-06-03
A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT06824883 2025-02-13
Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT06732492 2024-12-13
RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Recruiting
NCT05662540 2024-10-26
PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma
Ruijin Hospital
Phase NA Recruiting
NCT05833893 2023-04-27
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Chinese PLA General Hospital
Phase 2 Recruiting
NCT02859402 2022-08-18
RRTCLAlloSCT
Keimyung University Dongsan Medical Center
Phase 2 Recruiting